Testosterone isobutyrate

Last updated

ñ

Testosterone isobutyrate
Testosterone isobutyrate.svg
Testosterone isobutyrate molecule ball.png
Clinical data
Trade names Agovirin-Depot, Perandren M, Testocryst, Virex-Cryst
Routes of
administration 		Intramuscular injection
Drug class Androgen; Anabolic steroid; Androgen ester
ATC code
Pharmacokinetic data
Metabolites Testosterone
Duration of action ~2 weeks [1] [2] [3]
Identifiers
  • [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.013.293 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C23H34O3
Molar mass 358.522 g·mol−1
3D model (JSmol)
  • CC(C)C(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
  • InChI=1S/C23H34O3/c1-14(2)21(25)26-20-8-7-18-17-6-5-15-13-16(24)9-11-22(15,3)19(17)10-12-23(18,20)4/h13-14,17-20H,5-12H2,1-4H3/t17-,18-,19-,20-,22-,23-/m0/s1
  • Key:PYHZLMFTKOTWGQ-WAUHAFJUSA-N

Testosterone isobutyrate, sold under the brand names Agovirin-Depot and Perandren M among others, is an androgen and anabolic steroid medication and a testosterone ester which is used for indications such as low testosterone levels in men and delayed puberty in boys. [1] [4] It is available only in the Czech Republic and Slovakia. [1] The medication is administered by injection into muscle once every 1 to 2 weeks in males. [1] Unlike most other testosterone esters, which are provided as oil solutions, testosterone isobutyrate is formulated as a microcrystalline aqueous suspension. [1]

Contents

Medical uses

Testosterone isobutyrate is used in the treatment of hypogonadism in men and delayed puberty in adolescent boys. [1] It is also used in the treatment of Klinefelter's syndrome, aplastic anemia, Cushing's syndrome (as an anabolic to preserve lean body mass), postmenopausal osteoporosis in women, advanced breast cancer in women, breast pain in women, and cachexia. [1] Testosterone isobutyrate has been used in masculinizing hormone therapy for transgender men as well. [5] [6]

Available forms

Testosterone isobutyrate is provided in the form of a 25 mg/mL microcrystalline aqueous suspension packaged in 2 mL ampoules (5 ampoules per box). [1] This equates to a dose of 50 mg per ampoule. [1] Testosterone isobutyrate (25 mg) is also available in combination with estradiol benzoate (2.5 mg) under the brand name Folivirin (1 mL ampoules). [7] [8] [9] [10] [11]

Side effects

Side effects of testosterone isobutyrate include virilization among others. [1]

Pharmacology

Testosterone isobutyrate is a prodrug of testosterone, and hence is an agonist of the androgen receptor, the biological target of endogenous androgens like testosterone and dihydrotestosterone. [1] It produces both androgenic and anabolic effects, as well as weak estrogenic effects due to metabolism of testosterone into estradiol. [1]

In contrast to most other testosterone esters, which are used as amorphous oil solutions, testosterone isobutyrate is provided in the form of a microcrystalline aqueous suspension. [1] It has very low water solubility and forms a long-lasting microcrystalline depot within muscle upon intramuscular injection. [1] This repository slowly dissolves over time. [1] As a result, testosterone isobutyrate has a prolonged duration of action of approximately 2 weeks. [1] [2] [3] It is administered at intervals of once every 1 to 2 weeks in men. [1] Microcrystalline testosterone isobutyrate in aqueous suspension requires a larger needle (21 gauge) than oil solutions due to the presence of solid crystals in the suspension. [1] It can produce local irritation, pain, and redness upon injection. [1]

Chemistry

Testosterone isobutyrate, or testosterone 17β-(2-methylpropanoate), is a synthetic androstane steroid and a derivative of testosterone. [12] [13] It is an androgen ester; specifically, it is the C17β 2-methylpropanoate (isobutyrate) ester of testosterone. [12] [13]

History

Microcrystalline testosterone isobutyrate in aqueous suspension was first described in 1952. [1] [14] It was introduced for medical use shortly thereafter. [1] Around the same time, testosterone enanthate in oil solution was introduced for medical use. [1] It became the dominant long-acting injectable form of testosterone, and limited the commercial success of testosterone isobutyrate. [1] The combination of microcrystalline estradiol benzoate and testosterone isobutyrate in aqueous suspension was introduced under the brand name Femandren M by 1953. [15]

Society and culture

Brand names

Brand names of testosterone isobutyrate include Agovirin-Depot, Perandren M, Testocryst, and Virex-Cryst. [12] [13] [16] [17] It has also been marketed in combination with estradiol benzoate under the brand names Femandren M and Folivirin. [7] [8] [9] [10] [11]

Availability

Testosterone isobutyrate is available only in the Czech Republic and Slovakia. [1] [16] It was originally manufactured by the pharmaceutical company SPOFA [18] intermittently manufactured by Biotika, [1] and is now manufactured by BB Pharma. [19]

See also

Related Research Articles

<span class="mw-page-title-main">Estradiol benzoate</span> Chemical compound

Estradiol benzoate (EB), sold under the brand name Progynon-B among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for transgender women, and in the treatment of gynecological disorders. It is also used in the treatment of prostate cancer in men. Estradiol benzoate is used in veterinary medicine as well. When used clinically, the medication is given by injection into muscle usually two to three times per week.

<span class="mw-page-title-main">Estradiol cypionate</span> Chemical compound

Estradiol cypionate (EC), sold under the brand name Depo-Estradiol among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for trans women, and in hormonal birth control for women. It is given by injection into muscle once every 1 to 4 weeks.

<span class="mw-page-title-main">Estradiol hexahydrobenzoate</span> Chemical compound

Estradiol hexahydrobenzoate (EHHB), sold under a number of brand names including Benzo-Ginoestril A.P., BenzoGynoestryl Retard, Ginestryl-15-Depot, Menodin, and Tardoginestryl, is an estrogen medication which was previously used for indications such as menopausal hormone therapy and gynecological disorders. EHHB is given by injection into muscle at regular intervals, for instance once every few weeks.

<span class="mw-page-title-main">Estradiol phenylpropionate</span> Chemical compound

Estradiol phenylpropionate (EPP), also known as estradiol 17β-phenylpropionate and sold under the brand name Menformon Prolongatum, is an estrogen which is no longer marketed. It is an estrogen ester, specifically the C17β phenylpropionate ester of estradiol.

<span class="mw-page-title-main">Estradiol dienantate</span> Chemical compound

Estradiol dienanthate (EDE), sold under the brand names Climacteron among others, is a long-acting estrogen medication which was previously used in menopausal hormone therapy for women and to suppress lactation in women. It was formulated in combination with estradiol benzoate (EB), a short-acting estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), a long-acting androgen/anabolic steroid. EDE has not been made available for medical use alone. The medication, in combination with EB and TEBH, was given by injection into muscle once or at regular intervals, for instance once every 6 weeks.

<span class="mw-page-title-main">Testosterone phenylacetate</span> Chemical compound

Testosterone phenylacetate is an androgen and anabolic steroid and a testosterone ester. Analogously to estradiol benzoate having been one of the first estrogen esters to be introduced, testosterone phenylacetate was one of the first testosterone esters to be introduced. However, since its introduction, it has largely been replaced by other esters, such as testosterone propionate.

<span class="mw-page-title-main">Estradiol benzoate/progesterone</span> Drug combination

Estradiol benzoate/progesterone (EB/P4), sold under the brand names Duogynon and Sistocyclin among others, is a combination medication of estradiol benzoate (EB), an estrogen, and progesterone (P4), a progestogen. It has been formulated both as short-acting oil solutions and long-acting microcrystalline aqueous suspensions and is given by injection into muscle either once or continuously at regular intervals.

<span class="mw-page-title-main">Estradiol benzoate/testosterone isobutyrate</span> Combination drug

Estradiol benzoate/testosterone isobutyrate (EB/TiB), sold under the brand names Femandren M and Folivirin, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone isobutyrate (TiB), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is provided in the form of 1 mL ampoules containing 2.5 mg estradiol benzoate and 25 mg testosterone isobutyrate in a microcrystalline aqueous suspension and is administered by intramuscular injection once every 4 to 6 weeks. EB/TiB reportedly has a duration of about 14 to 21 days.

<span class="mw-page-title-main">Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone</span> Combination drug

Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone (EB/EDE/TEBH), sold under the brand names Climacteron, Lactimex, Lactostat, and Amenose, is an injectable combination medication of estradiol benzoate (EB), an estrogen, estradiol dienanthate (EDE), an estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), an androgen/anabolic steroid, which is used in menopausal hormone therapy for peri- and postmenopausal women and to suppress lactation in postpartum women. Clinical studies have assessed this formulation.

<span class="mw-page-title-main">Estradiol cypionate/testosterone cypionate</span> Combination drug

Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms, but can also be used for other estrogen indications in women. The medication has also been used to suppress lactation in postpartum women.

<span class="mw-page-title-main">Estradiol valerate/testosterone enanthate</span> Combination drug

Estradiol valerate/testosterone enanthate (EV/TE), sold under the brand names Primodian Depot and Ditate among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and testosterone enanthate (TE), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. The medication is also used to suppress lactation in postpartum women.

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women. It was also used to suppress lactation in postpartum women.

<span class="mw-page-title-main">Estradiol butyrylacetate/testosterone ketolaurate/reserpine</span> Combination drug

Estradiol butyrylacetate/testosterone ketolaurate/reserpine (EBA/TKL/R), sold under the brand name Klimanosid R-Depot, is an injectable combination medication of estradiol butyrylacetate (EBA), an estrogen, testosterone ketolaurate, an androgen/anabolic steroid, and reserpine, an antipsychotic, which was previously used in menopausal hormone therapy for women, particularly in those with pronounced neurovegetative symptoms. It contains 2 mg EBA, 50 mg TKL, and 0.4 mg reserpine in oil solution in each 1 mL ampoule and is administered by intramuscular injection at regular intervals. The medication was marketed in 1957.

Testosterone propionate/testosterone enanthate/testosterone undecylenate (TP/TE/TUe), sold under the brand name Durasteron, is an injectable combination medication of testosterone propionate (TP), testosterone valerate (TV), and testosterone undecylenate (TUe), all of which are androgens/anabolic steroids. It contains 20 mg TP, 80 mg TE, and 150 mg TUe in oil solution and is administered by intramuscular injection at regular intervals, for instance once every 3 or 4 weeks. Use of Durasteron by bodybuilders has been reported.

Estrone/progesterone/testosterone (E1/P4/T), sold under the brand name Tristeron or Tristerone, is an injectable combination medication of estrone (E1), an estrogen, progesterone (P4), a progestogen, and testosterone (T), an androgen/anabolic steroid, which was used in the treatment of functional uterine bleeding in women. It contained 6 mg estrone, 50 mg progesterone, and 25 mg testosterone in microcrystalline aqueous suspension and was administered by intramuscular injection. The medication was manufactured by Wyeth and was marketed by 1951. It is no longer available.

Estradiol benzoate/progesterone/testosterone propionate (EB/P4/TP), sold under the brand names Lukestra, Steratrin, Trihormonal, and Trinestryl, is an injectable combination medication of estradiol benzoate (EB), an estrogen, progesterone (P4), a progestogen, and testosterone propionate (TP), an androgen/anabolic steroid. It contained 1 to 3 mg EB, 20 to 25 mg P4, and 25 mg TP, was provided in the form of ampoules, and was administered by intramuscular injection. The medication was introduced by 1949 and was marketed in the United States, the United Kingdom, and Germany among other places. It is no longer available.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 314–322. ISBN   978-0-9828280-1-4.
  2. 1 2 Doepfmer EH (13 March 2013). "Fertilitätsstörungen beim Manne, Somatischer Teil". In Schuermann H, Doepfmer R (eds.). Fertilitätsstörungen beim Manne. Springer-Verlag. pp. 260–. ISBN   978-3-642-94784-1.
  3. 1 2 Ufer J (1960). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. Gruyter. p. 153. ISBN   9783111138770.
  4. ↑ "AGOVIRIN DEPOT Injekční suspenze (Testosteroni isobutyras)" (PDF). Biotika A.S. 16 March 2011. Archived from the original (PDF) on 2019-05-20. Retrieved 2019-05-20.
  5. ↑ Heresová J, Pobisová Z, Hampl R, Stárka L (December 1986). "Androgen administration to transsexual women. II. Hormonal changes". Exp. Clin. Endocrinol. 88 (2): 219–23. doi:10.1055/s-0029-1210600. PMID   3556412.
  6. ↑ Hampl R, Hána V, Heresová J, Brzek A, Marek J, Stárka L (January 1989). "Srovnání vylucování trí v Ceskoslovensku registrovaných androgenů" [Comparison of the excretion of 3 androgens registered in Czechoslovakia]. Sbornik Lekarsky (in Czech). 91 (1): 16–20. ISSN   0036-5327. PMID   2717876.
  7. 1 2 "FOLIVIRIN Injekční suspenze (Estradioli benzoas, testosteroni isobutyras)" (PDF). Biotika A.S. 16 April 2011. Archived from the original (PDF) on 2019-05-20. Retrieved 2019-05-20.
  8. 1 2 Kubíková D (2014). "Menopauzální symptomy a hormonální substituční terapie" [Menopausal symptoms and hormone replacement therapy]. Praktické Lékárenství[Practical Pharmacy] (in Czech). 10 (2): 68–73. ISSN   1801-2434.
  9. 1 2 Marek J (14 May 2010). "Farmakoterapie endokrinních onemocnění a léčba kortikosteroidy" [Pharmacotherapy of endocrine diseases and treatment with corticosteroids]. Farmakoterapie vnitřních nemocí: 4., zcela přepracované a doplněné vydání (in Czech). Grada Publishing a.s. pp. 380–. ISBN   978-80-247-9524-9. In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.
  10. 1 2 Kern W, Auterhoff H, Neuwald F, Schmid W, eds. (14 December 2013). "Hromone". Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte[Hager's handbook of pharmaceutical practice: For pharmacists, drug manufacturers, druggists, doctors and medical officials]. Springer-Verlag. pp. 1163–. ISBN   978-3-662-36329-4.
  11. 1 2 Hager HH, Kern W, List PH, Roth HJ (29 July 2013). "Androgene,anabole steroide". Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 109, 141, 178. ISBN   978-3-662-25655-8.
  12. 1 2 3 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN   978-1-4757-2085-3.
  13. 1 2 3 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN   978-3-88763-075-1.
  14. ↑ Drescher H (April 1952). "Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension" [Experiences with a New Testosterone Isobutyrate Crystal Suspension]. Dtsch. Med. Wochenschr. (in German). 77 (14): 431–2. doi:10.1055/s-0028-1115985. PMID   12988767. S2CID   260092180.
  15. ↑ Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197. Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines
  16. 1 2 "Testosterone". Drugs.com.
  17. ↑ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. p. 270. ISBN   978-94-011-4439-1.
  18. ↑ Lissak K (6 December 2012). Hormones and Brain Function. Springer Science & Business Media. p. 145. ISBN   978-1-4684-2007-4.
  19. ↑ "Agovirin Injection". Bbpharma.sk.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.